GENEXPLAIN RESEARCH
Research collaboration
As a highly active biomedical research company, geneXplain is proud to offer its expertise and products to all interested partners. You are welcome to invite us for collaboration in any of the applicable grant programs (we would act as a German SME partner) or include our software and databases in your grant applications for covering the license costs with the received funding.
Cancer research in geneXplain
As a deeply rooted biomedical research company, geneXplain GmbH is proud to share with you our latest news, recent and upcoming events, and breakthrough solutions for the cancer research field.
COVID-19 RESEARCH
As a bioinformatics company we perform our own in silico research on COVID-19. We applied Genome Enhancer tool to publicly available COVID-19 datasets to identify prospective drug targets and treatments for this infection. The results of our studies were shared by geneXplain’s CSO Dr. Alexander Kel during our recent masterclasses, the video records of which are available below.
ChromRare
The ChromRare project focuses on understanding chromatinopathies (CPs), rare genetic diseases caused by mutations in chromatin regulators, by investigating their genetic and epigenetic determinants to develop new diagnostic and therapeutic strategies. The project aims to create disease models and identify disrupted regulatory pathways, addressing critical needs for understanding and treating CPs.Further details about the ChromRare project are available at the project homepage.
HIT-GLIO
Targeting tumor-host interactions in pediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy
COPreDict
Development of COPD prognostic routine for optimal therapy prediction on the basis of lipid microbial biomarkers and AI-based modeling of immune response.
OxidoResist
Identification and validation of complementary therapies to
overcome resistance to a novel anticancer compound inducing
oxidative stress in cancer cells.
GlioResolve
The GLIORESOLVE project aims to develop new therapeutic strategies for glioblastoma (GBM), a highly aggressive brain tumor with a poor prognosis, by leveraging a novel tumor microenvironment (TME) classification system established in the Gliotrain Project. Key objectives include expanding immunotherapy options, optimizing pre-clinical models that mimic GBM TME subtypes, and testing new drug combinations tailored to these subtypes, all through a collaborative effort involving leading European researchers and advanced methodologies like multi-omics and computational modeling.
E-REDALERT
REspiratory microbiome and clinical Data AnaLysis for the prediction of acute exacERbaTions in COPD
FindingMS
An integrated approach to the prediction of disease activity in the early phases of multiple sclerosis
COLOSSUS
Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions